Possible Interruption of Measles Virus Transmission, Uganda, 2006–2009

Frederick N. Baliraine, Josephine Bwogi, Henry Bukenya, Ronald Seguya, Theopista Kabaliisa, Annet Kisakye, William B. Mbabazi, and Sheilagh B. Smit

To determine what measles virus genotype(s) circulated in Uganda after strategic interventions aimed at controlling/eliminating measles, we examined samples obtained during 2006–2009 and found only genotype B3.1, which had not been previously detected. Kenya was the likely source, but other countries cannot be excluded.

In October 2002, Uganda implemented a 5-year (2002–2006) accelerated measles control strategy that began with a vigorous attempt to interrupt all chains of measles transmission by using a 5-day countrywide vaccination campaign. This brisk catch-up campaign was preceded by vaccine potency tests; meticulous planning to ensure political, religious, and tribal leaders’ support; spirited social mobilization; training of health care workers and volunteers; and adequate provision of vaccination and cold chain materials at all vaccination posts, some of which were improvised structures (e.g., tents, schools, or under trees) for easy access. Community education was particularly vital to dispel commonly held myths that vaccinating children against measles or taking children having measles to the hospital (i.e., using foreign medicine) increases the risk for death. About 13.5 million (>0.5 million above target) children ages 6–168 months were vaccinated, giving a national measles vaccine coverage rate of 104% (1). This was followed by keep-up campaigns in 15 high-risk districts for children ages 6–23 months in February 2005 and in April 2005 for all previously unvaccinated children ages 9–59 months. Uganda was virtually measles free in 2003–2005, but outbreaks resurfaced in 2006. Subsequently, nationwide follow-up supplemental measles vaccination campaigns were conducted for children ages 6–59 months during August–November 2006 (1) and for children ages 9–47 months in June 2009.

Virologic surveillance before initiating accelerated measles control activities enables genotypes to be cataloged in a country both before and after vaccination campaigns, which together with standard epidemiologic data can help detect imported viruses and evaluate control strategies (2). In Uganda, measles virus isolation began in 2000 (3). Our study sought to determine the measles virus genotype(s) circulating in Uganda after strategic interventions aimed at controlling/eliminating measles in the country were implemented.

The Study

As part of routine measles case investigations, urine samples and throat swab specimens for virus isolation were collected along with serum samples (0–12 days after rash onset) from patients across Uganda during 2006 through 2009. Infections were confirmed serologically or by virus isolation (4,5). Of the serum samples tested, 1,053 (15%) of 6,999 were positive for measles immunoglobulin (Ig) M; most were collected during 2006 (Figure 1). Twenty-two isolates (37%) were obtained from 59 samples from patients who had IgM against measles virus; 1 isolate was obtained from a patient who did not have IgM against measles virus; and another isolate was obtained from a patient who did not have serologic testing. Virus isolation was successful only in specimens collected within 5 days of rash onset (Table).
All isolates belonged to genotype B3.1 (Figure 2), which had not been previously detected in Uganda (3). Twelve (57%) of 21 sequences obtained were identical (Table) and also identical to isolates from the 2005 measles outbreak in Kenya (Figure 2). However, 9 (43%) of 21 showed neither 100% similarity with the other 12 Ugandan isolates (Table) nor with any other isolate available in GenBank.

Since the inception of Uganda’s 2002–2006 accelerated measles control strategic plan, the number of measles cases in the country has declined dramatically (Figure 1). After the 2003 campaign, virtually no cases of measles occurred in Uganda for 3 years, until the outbreaks in 2006 (1). Our data show that 819 (78%) of 1,053 of the serologically confirmed cases for the 4-year surveillance period occurred during the 2006 outbreaks (Figure 1), confirming that the strategic interventions quickly subdued the 2006 transmission cycles. Moreover, the pattern of measles genotypes detected from 2000–2009 (2006–2009 reported in this study) suggests that transmission of the previously endemic genotype D10 in Uganda (3) has been interrupted and replaced by genotype B3.1. However, since molecular surveillance in Uganda only began 10 years ago (3), we cannot ascertain which genotypes were circulating in the country before 2000. By 2001, B3.1 was geographically restricted to the western and central African countries of Ghana, Nigeria, Cameroon, and Sudan (6,7); however, by the end of 2005, it had spread to Kenya, supposedly from Nigeria, where it caused a massive epidemic that was linked to subsequent infections in Europe and the Americas (8).

The fact that most isolates from Uganda were identical to those previously identified in neighboring Kenya indicates that Kenya was the most likely immediate source of the B3.1 viruses presently circulating in Uganda. However, the contribution of other African countries cannot be excluded, because molecular surveillance is still largely lacking in Africa (5).

Only 14 (23%) of 61 patients with laboratory-confirmed measles (whose specimens were screened for measles virus isolates) had been vaccinated, demonstrating a gap in vaccination coverage and possible vaccination failure in some cases and the need for timely catch-up vaccination campaigns even in the low-risk districts. In Uganda, routine childhood vaccination against measles began in 1983, but vaccine coverage was initially too low to interrupt indigenous transmission. The situation was not helped by the rampant poverty, limited health-care infrastructure, internal and external conflicts that have rocked the Great Lakes Region during the past 3 decades, high vaccination drop-out rates, and a high birth rate (second highest in the world, after Niger [9]). These conditions are typical in countries where vaccine-preventable infections remain a major problem (10). Nevertheless, education of Ugandan health workers, politicians, and development partners has been ongoing. This strategy has aroused strong interest and support for disease surveillance and

---

**Table. Epidemiologic data associated with measles virus isolates analyzed, Uganda, 2006–2009***

| Isolate name | District | Patient age, mo | Measles vaccine doses | Vaccination card seen | Date of onset, Interval, d | Measles IgM | GenBank accession no. | Identity†‡ |
|--------------|----------|----------------|-----------------------|-----------------------|--------------------------|------------|-----------------------|-----------|
| MVi/Bushenyi.UGA/43.06 | Bushenyi | 19 | 1 | No | 2006 Oct 4 | Pos | GU952229 | A |
| MVi/Hoima.UGA/7.09/1 | Hoima | 36 | X | No | 2009 Feb 5 | Pos | GU952246 | B |
| MVi/Hoima.UGA/7.09/2 | Hoima | 36 | X | No | 2009 Feb 2 | Neg | B |
| MVi/Kampala.UGA/26.06/1 | Kampala | 30 | X | No | 2006 Jun 1 | Pos | GU952239 | A |
| MVi/Kampala.UGA/26.06/2 | Kampala | 36 | X | No | 2006 Jun 4 | Pos | A |
| MVi/Kampala.UGA/26.06/3 | Kampala | 18 | 0 | No | 2006 Jun 2 | ND | GU952237 | C |
| MVi/Kasese.UGA/7.07/1 | Kasese | 25 | 0 | Yes | 2007 Feb 2 | Pos | GU952245 | A |
| MVi/Kasese.UGA/7.07/2 | Kasese | 240 | X | No | 2007 Feb 3 | Pos | A |
| MVi/Kitgum.UGA/28.06 | Kitgum | 60 | 2 | No | 2006 Jul 3 | Pos | GU952235 | A |
| MVi/Mukono.UGA/26.06 | Mukono | 96 | 0 | No | 2006 Jun 1 | Pos | GU952238 | D |
| MVi/Mukono.UGA/29.06 | Mukono | 276 | X | No | 2006 Jul 3 | Pos | GU952233 | E |
| MVi/Mukono.UGA/47.06 | Mukono | 48 | 1 | Yes | 2006 Nov 1 | Pos | GU952243 | F |
| MVi/Wakiso.UGA/26.06 | Wakiso | 36 | 2 | No | 2006 Jun 1 | Pos | GU952240 | A |
| MVi/Wakiso.UGA/27.06 | Wakiso | 96 | 0 | No | 2006 Jul 1 | Pos | GU952236 | C |
| MVi/Wakiso.UGA/29.06 | Wakiso | 33 | 0 | Yes | 2006 Jul 1 | Pos | GU952234 | A |
| MVi/Wakiso.UGA/31.06/1 | Wakiso | 19 | 1 | No | 2006 Jul 1 | Pos | GU952232 | G |
| MVi/Wakiso.UGA/31.06/2 | Wakiso | 25 | 0 | No | 2006 Aug 2 | Pos | GU952231 | A |
| MVi/Wakiso.UGA/32.06 | Wakiso | 11 | X | No | 2006 Aug 1 | Pos | GU952230 | A |
| MVi/Wakiso.UGA/41.06 | Wakiso | 27 | 0 | No | 2006 Oct 1 | Pos | GU952241 | A |
| MVi/Wakiso.UGA/45.06 | Wakiso | 120 | 2 | No | 2006 Nov 2 | Pos | GU952242 | H |
| MVi/Wakiso.UGA/49.06 | Wakiso | 216 | 1 | No | 2006 Dec 2 | Pos | GU952244 | A |

*All were genotype B3.1. IgM, immunoglobulin M; pos, positive; neg, negative; X, unknown; ND, not done.
†Time between rash onset and sample collection.
‡Nucleotide sequences sharing the same letter are identical.
control activities from the political leadership, resulting in the creation of a special budget line for surveillance (11). Since 2003, routine vaccination has been strengthened by extending primary health care grants to all districts, and the implementation of the “Reaching Every District” strategy (I2), among other interventions. Consequently, Uganda has recorded a tremendous rise in vaccination coverage, from 64% in 1997 to ≥85% by 2007 (I). This aggressive vaccination effort has been instrumental in interrupting indigenous measles strain transmission in the country.

All virus isolates from Uganda during 2000–2002, before accelerated measles control, belonged to genotype D10 (3). At that time, viruses isolated in countries bordering Uganda, such as Kenya, Sudan, and the Democratic Republic of the Congo, belonged to genotypes D4, B3, and B2 (I3). However, without enhanced regional surveillance, should genotype D10 be isolated again, it would be difficult to determine whether it had truly been interrupted, without knowing if D10 was presently circulating in other African countries, which could serve as bases from which to reintroduce it into Uganda.

Conclusions

Our results show that, even under difficult circumstances (e.g., poverty), optimal resource allocation and mobilization of political will can interrupt vaccine-preventable diseases in Africa. These data provide molecular evidence that Uganda’s 2002–2006 vaccination strategy was successful in interrupting indigenous measles transmission, but immunity gaps in the population allowed the establishment of an imported virus that was previously confined to western and central Africa. If national immunization programs across the region synchronized their vaccination strategies to eliminate sources of reintroduction, measles could be quickly eliminated from the entire continent. Vaccination success stories have already been noted in several African countries with routine coverage >80% (I4, I5). Therefore, continued education and cooperation are needed between countries, national policy makers, health care workers, and local communities throughout the continent to win the fight against measles.

Acknowledgments

We thank the health care workers who helped with specimen collection and the following persons for helping with the investigations: Nasan Natseri, Molly Birungi, Prossy Namuwulya, Mayi Tihanagwa, and Betty Muliranyi. We thank Paul Rota for providing us with PCR reagents and helpful comments on the draft manuscript. In addition, we thank the 2 anonymous reviewers for their informed comments that helped to improve the manuscript.

Financial assistance for this work was obtained from Uganda Ministry of Health and the Global Measles Partnership through the World Health Organization. Support for testing was also obtained from the Medical Research Council, Uganda, National Institute of Communicable Diseases, South Africa and Centers for Disease Control, Uganda and United States.
Dr. Baliraine was a scientific officer at Uganda Virus Research Institute, Entebbe, when this research was conducted and is currently a postdoctoral researcher in the University of California San Francisco Department of Medicine, Division of Infectious Diseases. His research interests include molecular epidemiology, diagnostics, and population genetics of infectious diseases pathogens (measles, rubella, malaria), as well as clarifying the mechanisms of antimalarial drug resistance.

References

1. Mbabazi WB, Nanyunja M, Makumbi I, Braka F, Baliraine FN, Kisakye A, et al. Achieving measles control: lessons from the 2002–06 measles control strategy for Uganda. Health Policy Plan. 2009;24:261–9. DOI: 10.1093/heapol/czp008
2. Rota PA, Featherstone DA, Bellini WJ. Molecular epidemiology of measles virus. In: Griffin DE, Oldstone MBA, editors. Measles: pathogenesis and control. Berlin: Springer-Verlag; 2009. p. 129–50.
3. Muwonge A, Nanyunja M, Rota PA, Bwogi J, Lowe L, Liflick SL, et al. New measles genotype, Uganda. Emerg Infect Dis. 2005;11:1522–6.
4. World Health Organization. Manual for the laboratory diagnosis of measles and rubella virus infection. 2nd ed. Geneva (Switzerland); The Organization; 2007.
5. Smit SB, Hardie D, Tiemessen CT. Measles virus genotype B2 is not inactive: evidence of continued circulation in Africa. J Med Virol. 2005;77:550–7. DOI: 10.1002/jmv.20491
6. Kouomou DW, Nerrienet E, Mfoupouendoun J, Tene G, Whittle H, Wild TF. Measles virus strains circulating in central and west Africa: geographical distribution of two B3 genotypes. J Med Virol. 2002;68:433–40. DOI: 10.1002/jmv.10222
7. El Mubarak HS, van de Bildt MW, Mustafa OA, Ves HW, Mukhtar MM, Ibrahim SA, et al. Genetic characterization of wild-type measles viruses circulating in suburban Khartoum, 1997–2000. J Gen Virol. 2002;83:1437–43.
8. Rota J, Lowe L, Rota P, Bellini W, Redd S, Dayan G, et al. Identical genotype B3 sequences from measles patients in 4 countries. Emerg Infect Dis. 2006;12:1779–81.
9. Central Intelligence Agency. The world fact book: Uganda [cited 2010 Aug 18]. https://www.cia.gov/library/publications/the-world-factbook/geos/ug.html
10. Ferrari MJ, Grais RF, Bharti N, Conlan AJ, Bjornstad ON, Wolfson LJ, et al. The dynamics of measles in sub-Saharan Africa. Nature. 2008;451:679–84. DOI: 10.1038/nature06509
11. World Health Organization. Implementing integrated disease surveillance and response. Wkly Epidemiol Rec. 2003;78:233–40.
12. World Health Organization. The RED strategy [cited 2010 May 13]. http://www.who.int/immunization_delivery/systems_policy/red/en
13. World Health Organization. New genotype of measles virus and update on global distribution of measles genotypes. Wkly Epidemiol Rec. 2005;80:348–51.
14. Biellik R, Madema S, Taele A, Kutsulukuta A, Allies E, Eggers R, et al. First 5 years of measles elimination in southern Africa: 1996–2000. Lancet. 2002;359:1564–8. DOI: 10.1016/S0140-6736-(02)08517-3
15. Otten MW Jr, Okwo-Bele JM, Kezzaara R, Biellik R, Eggers R, Nshimiriana D. Impact of alternative approaches to accelerated measles control: experience in the African region, 1996–2002. J Infect Dis. 2003;187:S36–43. DOI: 10.1086/368272

Address for correspondence: Frederick N. Baliraine, University of California, Department of Medicine, San Francisco General Hospital, 1001 Potrero Ave, PO Box 0811, San Francisco, CA 94143-0811, USA; email: fbaliraine@daad-alumni.de